Intratympanic corticosteroid (ITC) injections are recommended as salvage therapy for patients with incomplete recovery 2-6 weeks after the onset of sudden sensorineural hearing loss (SSHL). AIMS/OBJECTIVES: To evaluate patient experiences with ITC therapy and assess treatment side effects. MATERIAL AND
✦ The floor
Discussion
Signed responses from readers of the wire.
Patient-reported experience data from a single centre can inform counselling and consent processes for salvage intratympanic steroid therapy, but the single-centre design limits generalisability; no immediate protocol change is warranted pending broader evidence.
Incorporating patient-reported experience measures into sudden sensorineural hearing loss management highlights that procedural tolerability and communication quality are as clinically important as audiometric outcomes.
- 01Single-centre prospective design capturing patient-reported experience with intratympanic steroid injections.
- 02Focuses on salvage therapy context — patients who did not respond adequately to initial treatment.
- 03Patient-reported experience measures complement traditional audiometric outcome data.
- 04Published in Acta Otolaryngologica, a peer-reviewed otolaryngology journal.
- 05Findings may guide shared decision-making and pre-procedure counselling in sudden SNHL.
Intratympanic corticosteroid injections are used as salvage therapy for sudden sensorineural hearing loss.
guidelinesupportedPatient-reported experience data can improve understanding of intratympanic injection tolerability.
studypartially supported- PMID
- 42969307
- DOI
- 10.1080/00016489.2026.2749996.
- Journal
- Acta Otolaryngologica
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Patients receiving intratympanic corticosteroid injections as salvage therapy for sudden sensorineural hearing loss at a single centre
- Intervention
- Intratympanic corticosteroid injections as salvage therapy
Primary outcomes
Patient-reported experience with intratympanic corticosteroid injections